6160:HKEXBeOne Medicines Ltd. Analysis

BeOne Medicines (6160.HK) trades at HK$183.5, which is well above its DCF‑derived fair value of HK$20.84, implying a substantial valuation gap despite a projected upside of 36.7% to the median analyst target of HK$244. The stock carries an eye‑popping trailing PE of 123 versus an industry average of 25, while its P/B of 0.60 suggests a book‑value discount. Technicals show a bullish price trend above the 20‑day SMA (198.8) but a bearish MACD (histogram –2.84) and a sub‑50 RSI of 39.6, indicating possible short‑term weakness near the identified support level of HK$171.4. Volume is rising and volatility is high at 46% (30‑day), yet beta is extremely low (0.055), reflecting limited systematic risk. The company boasts strong fundamentals: 32.8% revenue growth, 87.5% gross margin, solid cash (HK$4.55 bn) and a pipeline of commercial and clinical oncology assets, supported by partnerships with Amgen, BMS, Novartis and others. Upcoming Q4 2025 earnings on Feb 26, 2026 will be a key catalyst, and the current “Extreme Greed” sentiment (Fear‑Greed Index 76.9) adds momentum pressure.